US sticks by rosiglitazone
The US Food and Drug Administration has decided to keep rosiglitazone on the market, despite new research adding to concerns over its effect on the heart.
An advisory panel convened by the FDA voted 22 to one to allow continued marketing of the drug, and 20 to three against a suggestion that available studies showed a signal of harm.
But the panel did recommend the drug should come with strong warnings over its potential risks.
The safety of rosiglitazone has been called into question by a number of studies pointing to increased cardiovascular risk, including new research suggesting it could raise the risk of heart failure.
A US study published in Diabetes Care concluded the risk of heart failure might be up to 100% higher in patients taking glitazones such as rosiglitazone.